The 340B program “is buckling under its own weight and overdue for reform,” biotechnology industry trade group BIO said last week in its blog.
BIO, which is marking its 30th anniversary in 2023, has experienced inner turmoil in recent
…The 340B program “is buckling under its own weight and overdue for reform,” biotechnology industry trade group BIO said last week in its blog.
BIO, which is marking its 30th anniversary in 2023, has experienced inner turmoil in recent
…Federal Medicare officials plan to issue a proposed rule in April regarding “potential remedies” for illegal Part B drug payment cuts for 340B hospitals from 2018 through late September 2022.
The Centers for Medicare & Medicaid Services revealed April as
…Drug manufacturer Eli Lilly late last month again updated its conditions on 340B pricing when covered entities use contract pharmacies.
Lilly was the first company to impose such conditions, starting with one drug in July 2020 then expanding to
…Brand drug manufacturers have asked a federal appeals court to overturn a judge’s ruling last month that Arkansas’s novel 340B anti-discrimination law is not preempted by the 340B statute nor by the U.S. Food and Drug Administration’s Risk Evaluation and
…Swiss eye care drug manufacturer Alcon is providing refunds for charges above 340B ceiling prices on 22 NDCs for varying sales periods from Q3 2019 through Q3 2022.
The U.S. Health Resources and Services Administration posted Alcon’s public notice about
…The U.S. House was frozen stuck this morning after the new Republican majority splintered yesterday, the first day of the 118th Congress, over who should be the next House speaker.
Representatives cannot be sworn in and the House cannot begin
…President Biden on Dec. 29 signed a $1.7 trillion omnibus appropriations bill for fiscal year 2023 that gave the 340B drug pricing program a slight funding boost.
The U.S. Health Resources and Services Administration’s Office of Pharmacy Affairs will get
…The U.S. Centers for Medicare & Medicaid Services starting Jan. 1, 2024, will require all 340B covered entities—hospital and grantee—to use claims modifiers to identify drugs as having been purchased through 340B when they bill for separately payable Medicare Part
…*Sign up for news summaries and alerts from 340B Report